Angiotech reports success with drug-coated catheter

10/10/2007 | Boston Globe (tiered subscription model), The

Device firm Angiotech Pharmaceuticals said it plans to file a premarket notification with the FDA for its 5-Fluorouracil-coated Central Venous Catheter after positive clinical trial results. The company said the 5-FU drug is intended to prevent bacterial growth in implanted catheters.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI